<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1956">
  <stage>Registered</stage>
  <submitdate>5/05/2008</submitdate>
  <approvaldate>5/05/2008</approvaldate>
  <nctid>NCT00673608</nctid>
  <trial_identification>
    <studytitle>Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload</studytitle>
    <scientifictitle>A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade® (Deferasirox) (The MILE Study)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CICL670AAU01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hemoglobinopathies</healthcondition>
    <healthcondition>Myelodysplastic Syndromes</healthcondition>
    <healthcondition>Other Inherited or Acquired Anaemia</healthcondition>
    <healthcondition>MPD Syndrome</healthcondition>
    <healthcondition>Diamond-Blackfan Anemia</healthcondition>
    <healthcondition>Other Rare Anaemias</healthcondition>
    <healthcondition>Transfusional Iron Overload</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Anaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - deferasirox

Experimental: Deferasirox - 


Treatment: drugs: deferasirox
Deferasirox up to 40mg/kg/day, PO, Dispersible tablets, taken once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in cardiac iron load and cardiac ejection fraction by MRI recorded at baseline and after 53 weeks.</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in ventricular ejection fraction values, ventricular volumes and masses from baseline values after 53 weeks.</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in cardiac T2* from baseline to 53 weeks in the MDS and other anaemias subgroup, compared to the thalassaemia subgroup.</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in serum ferritin from baseline values to 53 weeks.</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in Liver Iron Content (LIC) by MRI from baseline values to 53 weeks</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The relationship between the dosing regimen of Exjade® and changes in cardiac T2* and LIC R2 MRI</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in markers of iron load levels between baseline and 53 weeks.</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The safety and tolerability of deferasirox therapy from baseline to 53 weeks</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Male or female WITH haemoglobinopathy, Myelodysplastic Syndromes or other inherited or
             acquired anaemia (e.g. MPD, Diamond-blackfan anaemia and other rare anaemias) patients
             = 18 years and weighing &gt;40kg.

          -  Lifetime minimum of &gt; 20 units of packed red blood cell transfusions

          -  Normal or minimally abnormal cardiac function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Contraindication to MRI scans

          -  High risk myelodysplastic syndromes patients and patients with other haematological
             and non-haematological malignancies who are not expected to benefit from chelation
             therapy due to the rapid progression of their disease

          -  Patients with uncontrolled high blood pressure

          -  An organ transplant less than 3 months previously

        Other protocol-defined inclusion/exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>118</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Novarts Investigative Site - Adelaide</hospital>
    <hospital>Novarts Investigative Site - Brisbane</hospital>
    <hospital>Novarts Investigative Site - Melbourne</hospital>
    <hospital>Novarts Investigative Site - Sydney</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the change in cardiac iron load over a 53 week period measured by
      MRI in 2 cohorts of patients</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00673608</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmeceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>